Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126848 | 0.93 | CASP3 (0.51) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5111610 | 0.89 | CASP3 (0.58) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL18669177 | 0.82 | CASP3 (0.52) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5125767 | 0.80 | CASP3 (0.54) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL2570381 | 0.77 | CASP3 (0.63) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5114960 | 0.77 | CASP3 (0.54) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL877431 | 0.77 | CASP3 (0.48) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5118846 | 0.77 | CASP3 (0.56) | CASP3CA12CA1CA2CA9 | |
| SCHEMBL5112878 | 0.75 | CASP3 (0.51) | CASP3CHRM5CA12CA1CA2 | |
| SCHEMBL5119321 | 0.74 | CASP3 (0.57) | CASP3ADRA1DADRA1AADRA1BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361783-B2 | (2S)-2-ethylphenylpropionic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| EP-1508566-B1 | (2S)-2-ETHYLPHENYLPROPIONIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-20060084702-A1 | (2S)-2-ethylphenylpropionic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| EP-1508566-A1 | (2S)-2-ETHYLPHENYLPROPIONIC ACID DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084702-A1 | (2S)-2-ethylphenylpropionic acid derivative | PPARA, PPARG, PPARD | CASP3 2013/4885CHRM5 2186/4885ADRA1D 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.